Refractory/Relapsed Disease

NEW ORLEANS — In this video, Samer Al Hadidi, MD, MS, FACP, discusses an analysis of access to chimeric antigen receptor T-cell therapy presented at the ASH Annual Meeting and Exposition.

In this video Aaron T. Gerds, MD, assistant professor in medicine at the Cleveland Clinic Taussig Cancer Institute, discusses a new irreversible FLT3 inhibitor that was tested in a first-in-human study.

Healio spoke with Taimur Sher, MBBS, MD, a hematologist, internist and oncologist at the Mayo Clinic Cancer and Multispecialty Amyloidosis Center, , on assessing the three most important factors in amyloid light chain (AL) amyloidosis patients and how relapses can guide treatment paths.

Healio spoke with Shazia K. Nakhoda, MD, about CLL highlights from recent conferences.